Treatment of Severe Infection With Antihyperlipidemia Drug
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by
decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic
acid, phospholipomannan are the main cause of the ongoing inflammation that causes the severe
damage and outcome. these substances are removed from the blood by the LDL receptors. By
administering PCSK9 inhibitors to patients with sepsis/septic shock this inflammatory
response can be stopped and by doing so improve the patients outcome.